Pfizer Inc. (PFE) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $27.13. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PFE = $17.48 (-35.6% from the current price, the stock appears overvalued). Analyst consensus target is PFE = $28 (+1.4% upside).
Valuation: PFE trades at a trailing Price-to-Earnings (P/E) of 20.1 (S&P 500 average ~25).
Financials: revenue is $62.6B, -11.5%/yr average growth. Net income is $7.8B, growing at +60.8%/yr. Net profit margin is 12.4% (healthy). Gross margin is 70.3% (+4.5 pp trend).
Balance sheet: total debt is $67.4B against $86.5B equity (Debt-to-Equity (D/E) ratio 0.78, moderate). Current ratio is 1.16 (adequate). Debt-to-assets is 32.4%. Total assets: $208.2B.
Analyst outlook: 16 / 39 analysts rate PFE as buy (41%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 61/100 (Pass), Growth 58/100 (Partial), Past 100/100 (Pass), Health 50/100 (Partial), Moat 94/100 (Pass), Future 34/100 (Fail), Income 55/100 (Partial).
